Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 3/20 | 0.77 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 12/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.34 |
| ▸ | CETP | P11597 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4886580 | 0.91 | VDR (0.63) | VDRPGRRORCNR1H2NR1H3 | |
| SCHEMBL4888522 | 0.87 | VDR (0.59) | VDRPGRRORCNR1H2NR1H3 | |
| SCHEMBL4894574 | 0.87 | VDR (0.66) | VDRPGRRORCPPARGNR1H2 | |
| SCHEMBL4881083 | 0.87 | VDR (0.61) | VDRPGRRORCPPARGNR1H2 | |
| SCHEMBL2855063 | 0.87 | VDR (1.00) | VDRCETP | |
| SCHEMBL4893090 | 0.86 | VDR (0.58) | VDRNR1H2NR1H3 | |
| SCHEMBL4888589 | 0.86 | VDR (0.58) | VDRPGRRORCNR1H2NR1H3 | |
| SCHEMBL4883569 | 0.85 | VDR (0.60) | VDRNR1H2NR1H3 | |
| SCHEMBL4884684 | 0.84 | VDR (0.55) | VDRPGRRORCNR1H2NR1H3 | |
| SCHEMBL15057603 | 0.84 | VDR (0.54) | VDRPGRRORCPPARGNR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4652687-B2 | — | — | 2011-03-16 | — | — | JP | claimed |
| US-20080194528-A1 | Pharmaceutical compositions comprising organopolysiloxane elastomers and solubilized bioactive compounds | GALDERMA RESEARCH AND DEVELOPMENT (FR) | 2008-08-14 | — | — | US | claimed |
| EP-1885374-A2 | PHARMACEUTICAL COMPOSITION COMPRISING AN OLEAGINOUS OINTMENT AND VITAMIN D OR THE DERIVATIVES THEREOF IN SOLUBILISED FORM | Galderma Research & Development (FR) | 2008-02-13 | — | — | EP | claimed |
| WO-2006123031-A2 | PHARMACEUTICAL COMPOSITION COMPRISING AN OLEAGINOUS OINTMENT AND VITAMIN D OR THE DERIVATIVES THEREOF IN SOLUBILISED FORM | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2006-11-23 | — | — | WO | claimed |
| JP-2005511731-A | — | — | 2005-04-28 | — | — | JP | claimed |
| EP-1456160-A2 | VITAMIN D ANALOGUES | Galderma Research & Development, S.N.C. (FR) | 2004-09-15 | — | — | EP | claimed |
| WO-2003050067-A2 | VITAMIN D ANALOGUES | GALDERMA RESEARCH & DEVELOPMENT, SNC (FR) | 2003-06-19 | — | — | WO | claimed |
| US-20080194528-A1 | Pharmaceutical compositions comprising organopolysiloxane elastomers and solubilized bioactive compounds | GALDERMA RESEARCH AND DEVELOPMENT (FR) | 2008-08-14 | — | — | US | disclosed |
| EP-1885374-A2 | PHARMACEUTICAL COMPOSITION COMPRISING AN OLEAGINOUS OINTMENT AND VITAMIN D OR THE DERIVATIVES THEREOF IN SOLUBILISED FORM | Galderma Research & Development (FR) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006123031-A2 | PHARMACEUTICAL COMPOSITION COMPRISING AN OLEAGINOUS OINTMENT AND VITAMIN D OR THE DERIVATIVES THEREOF IN SOLUBILISED FORM | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2006-11-23 | — | — | WO | disclosed |
| US-6924400-B2 | Triaromatic vitamin D analogues | GALDERMA RESEARCH & DEVELOPMENT, SNC (FR) | 2005-08-02 | — | — | US | disclosed |
| US-20030195259-A1 | Triaromatic vitamin D analogues | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2003-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195259-A1 | Triaromatic vitamin D analogues | CYP24A1, CYP2R1, VDR | VDR 3/4885PGR 409/4885RORC 93/4885 |
| US-20080194528-A1 | Pharmaceutical compositions comprising organopolysiloxane elastomers and solubilized bioactive compounds | CYP24A1, VDR, SOST | VDR 2/4885PGR 2407/4885RORC 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.